APEIRON Biologics AG Release: Success in Avoiding Radiation Skin Damage for Breast Cancer Patients
3/5/2013 11:33:56 AM
More...
|
APEIRON Biologics AG Closes Regional License Agreement for Antibody-Based Immunotherapy
1/18/2013 9:31:54 AM
More...
|
APEIRON Biologics AG Establishes Biotech-Spinoff Attoquant Diagnostics
12/4/2012 11:55:18 AM
More...
|
APEIRON Biologics AG Initiates Clinical Study to Investigate Prevention of Radiation-Induced Skin Damage in Breast Cancer Patients
2/27/2012 12:10:39 PM
More...
|
APEIRON Biologics AG Release: Start of Phase IIa Study in Acute Lung Injury Patients Marks Development Milestone
12/19/2011 10:46:41 AM
More...
|
Evotec AG (EVTG.F) and APEIRON Biologics AG Start Next Project on the Cbl-b Target
10/20/2011 10:44:04 AM
More...
|
Children's Oncology Group and APEIRON Biologics AG to Jointly Conduct Phase II Study in Neuroblastoma With hu14.18-IL2 (APN301)
9/29/2011 11:16:18 AM
More...
|
Oncology Alliance: APEIRON Biologics AG, CCRI and SIOGEN Biotech Join Forces Against Neuroblastoma
6/22/2011 9:56:20 AM
More...
|
Apeiron Biologics Acquires Option to License Rights to Novel Oncology Compounds from Cleveland Clinic
3/15/2011 10:28:55 AM
More...
|
Experienced Venture Capitalist/Pharma Manager Joins Apeiron Biologics' Business Development Team
1/10/2011 10:55:47 AM
More...
|
|